ArticlePharmacoEconomics2020

Cost-Utility Analysis of Ravulizumab Compared with Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria.

Thomas O'Connell et al.PubMed ↗Publisher ↗

No numbers read from the abstract.